Download PDF
Nuklearmedizin 1991; 30(05): 189-192
DOI: 10.1055/s-0038-1629574
ÜBersichtsartikel - Review Articles
Schattauer GmbH

An Evaluation of the Tumour Affinity of the Radioactive Cobalt Chelate of Tallysomycin S10b in Lymphoma-Bearing Mice

R. Veerapandian
1   From the Isotope Division, Cancer Institute, Adyar, Madras, India
,
V. M. Sivaramakrishnan
1   From the Isotope Division, Cancer Institute, Adyar, Madras, India
› Author Affiliations
Further Information

Publication History

Received: 22 May 1991

Publication Date:
05 February 2018 (online)

Also available at
    Permissions and Reprints

The tumour affinity of the radioactive cobalt chelate of tallysomycin S10b (Tim S-10b). a promising structural analogue of Bleomycin, was assessed using a mouse lymphoma model. The highest concentrations (%dose/gram tissue) were observed in the kidneys, followed by the tumour (4.1 %/g 1 h p.i.) at 1 h, 4 h and 48 h. The tumour had the highest concentration among all tissues at 24 h. The biodistribution profile of 60Co-Tlm S10b was distinctly different from that obtained with 60CoCl2, demonstrating the in vivo stability of the chelate. More than half of the chelate (56.8% of the injected dose) was excreted in the urine at 1 h. The highest tumour/non-tumour ratios were obtained for blood (41.3, 4 h), bone (30.5, 4 h) and muscle (29.2, 48 h). Scintigraphy at 24 h, using 57Co-Tlm S10b, showed the tumour, liver, kidney and bladder clearly. The similarities and differences exhibited by Co-Tim S10b with reference to the literature on cobalt chelates of Bleomycin and naturally occurring tallysomycin (A + B) are discussed.

Zusammenfassung

Die Tumoraffinität des radioaktiven Kobalt-Chelats von Tallysomycin S10b (Tim S10b), eines vielversprechenden Strukturanalogons des Bleomycins, wurde mit einem Lymphom-Modell der Maus überprüft. Eine, vier und 48 h nach der Injektion wurden die höchsten Anreicherungen (% der inj. Aktivität/g Gewebe) in den Nieren und im Tumor (4,1 %/g nach 1 h) gemessen. 24 h p.i. enthielt der Tumor von allen Geweben die höchste Konzentration. Die In-vivo-Verteilung von 60Co-Tlm S10b unterschied sich eindeutig von der Verteilung von 60CoCl2. Dies demonstriert die In- vivo-Stabilität des Chelats. Eine Stunde nach der Injektion war mehr als die Hälfte des Chelats (56,8% der injizier- ten Aktivität) über den Urin ausgeschieden. Das höchste Tumor/Nicht- tumor-Speicherverhältnis betrug für das Blut 41,3 (4 h), für den Knochen 30,5 (4 h) und für den Muskel 29,2 (48 h p.i.). 24h nach der Injektion von 57Co-Tlm S10b konnten szintigra- phisch Tumor, Leber, Niere und Blase sichtbar gemacht werden. Ähnlichkeiten und Unterschiede für Co-Tlm S10b Vergleich zum Co-Chelat des Bleomycin und dem natürlich vorkommenden Tallysomycin (A + B) werden unter Bezug auf Literaturangaben diskutiert.

 

  • REFERENCES

  • 1 Alberts DS, Chen HSG, Woolfenden JM. et al. Pharmacokinetics of Bleomycin in man. Cancer Chemother Pharmacol 1979; 03: 33-40.
    Google Scholar
  • 2 Buroker RA, Comereski CR, Barnett D. et al. The toxicological evaluation of Tallysomycin S10b – biosynthetic Tallysomycin derivative. Drug Chem Toxicol 1984; 07: 259-72.
    CrossrefPubMedGoogle Scholar
  • 3 Hall JN, Woolfenden JM, Rothman LS, Douros JD. Comparison of tumor localizing properties of cobalt-57 Bleomycin and four analogues; Bleomycinic acid, Phleomycin, Pepleomycin and Tallysomycin. J Nucl Med 1980; 21: 37.
    Google Scholar
  • 4 Hou DY, Hoch H, Johnston G. et al. A new tumor imaging agent – 111In-Bleomycin complex. Comparison with 67Ga-citrate and 57Co-Bleomycin in tumor-bearing animals. J Surg Oncol 1984; 27: 189-95.
    CrossrefPubMedGoogle Scholar
  • 5 Kono A, Matsushima Y, Kojima M, Maeda T. Cobalt chelate of Bleomycin. I. Physicochemical properties and distribution in tumor bearing mice. Chem Pharm Bull 1977; 25: 1725-31.
    CrossrefPubMedGoogle Scholar
  • 6 Liniecki J, Rembelska M, Koniarek B. Uptake of labelled Tallysomycin by solid Ehrlich ascites tumors in mice. Nucl Med 1983; 22: 159-61.
    Google Scholar
  • 7 Miyaki T, Numata K, Nishiyama Y. et al. Tallysomycin, a new antitumor antibiotic complex related to Bleomycin. V. Production, characterization and antitumor activity of Tallysomycin S10b, a new biosynthetic Tallysomycin derivative. J Antibiot 1981; 34: 665-74.
    CrossrefPubMedGoogle Scholar
  • 8 Miyaki T, Tenmyo O, Numata K. et al. Tallysomycin, a new antitumor antibiotic complex related to Bleomycin. IV. New biosynthetic derivatives of Tallysomycin. J Antibiot 1981; 34: 658-64.
    CrossrefPubMedGoogle Scholar
  • 9 Nouel JP. Radioactive metal-bleomycin complex for the diagnosis of cancer. GANN Monogr Cancer Res 1976; 19: 301-16.
    Google Scholar
  • 10 Nouel JP, Renault H, Robert J, Jeanne C, Wicart L. La bléomycine marquée au 57Co. Intérët dans le diagnostic des tumeurs malignes et de leur extension. Nouv Presse Med 1972; 01: 95-8.
    Google Scholar
  • 11 Nunn AD. The relative stability of Bleomycin metal complexes to metal exchange. Eur J Nucl Med 1977; 02: 53-7.
    CrossrefGoogle Scholar
  • 12 Raban P, Brousil J, Švihovcová P. Chemical and biological properties of Bleomycin labelled with 57Co. Eur J Nucl Med 1979; 04: 191-97.
    CrossrefPubMedGoogle Scholar
  • 13 Schurig JE, Rose WC, Hirth RS. et al. Tallysomycin S10b,: experimental antitumour activity and toxicity. Cancer Chemother Pharmacol 1984; 13: 164-70.
    CrossrefPubMedGoogle Scholar
  • 14 Tom WM, Montgomery MR. Disposition of the pulmonary toxin Bleomycin. Drug Metab Disposition 1979; 07: 90-3.
    Google Scholar